以嶺藥業(002603.SZ):一次性醫用口罩(非無菌)獲得CE符合性認可
格隆匯 9 月 3日丨以嶺藥業(002603.SZ)公佈,公司控股97.79%的子公司以嶺健康科技有限公司(“以嶺健康”)近日收到歐盟公告機構 CMCMEDICAL DEVICES & DRUGS SL頒發的CE符合性聲明報告。產品名稱:一次性醫用口罩(非無菌);證書編號:CMC/CE/2020/26082020.2;有效期:2020年8月26日至2021年8月25日。
以嶺健康生產的一次性醫用口罩(非無菌)獲得CE符合性認可,表明該公司此產品已具備歐盟市場的准入條件,有利於相關產品在歐盟市場的推廣和銷售。同時可藉助連花品牌勢能,增強產品的綜合競爭力,為公司增加新的利潤增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.